Tact IP, LLC
Records under this name other than the patents Tact IP, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,641,944 | Fuel Cell Drive System Term ended Term ended Apr 19, 2022 · High confidence | Term ended | Term ended Apr 19, 2022 | High confidence |
| US 8,119,127 | Cytokine antagonists for neurological and neuropsychiatric disorders Term ended Term ended Jan 16, 2020 · From the USPTO record | Term ended | Term ended Jan 16, 2020 | From the USPTO record |
| US 6,177,077 | TNT inhibitors for the treatment of neurological disorders Term ended Term ended Dec 31, 2019 · From the USPTO record | Term ended | Term ended Dec 31, 2019 | From the USPTO record |
| US 7,214,658 | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection Lapsed on the fee record Ended May 8, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2019 | From the USPTO record |
| US 6,419,944 | Cytokine antagonists for the treatment of localized disorders Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |
| US 6,537,549 | Cytokine antagonists for the treatment of localized disorders Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |
| US 6,982,089 | Cytokine antagonists for neurological and neuropsychiatric disorders Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |
| US 7,629,311 | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |
| US 8,236,306 | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |
| US 8,349,323 | Cytokine antagonists for neurological and neuropsychiatric disorders Term ended Ended no later than Feb 24, 2019 · From the USPTO record | Term ended | Ended no later than Feb 24, 2019 | From the USPTO record |